Inimmune Corporation ("Inimmune"), a clinical-stage biotechnology company focused on developing innovative immunotherapies, ...
Patient-centric trial aiming to evaluate whether bezisterim can help delay disease progression reaches enrollment milestone -- Topline Results ...
Interim safety and efficacy data to be reported in Q1VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa ...
Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE) ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal ...
Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2 ...
Processa Pharmaceuticals (PCSA) reported that it completed the enrollment and dosing of the 20 patients required for the planned formal interim ...
The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep ...
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...
A recent VDOT study coupled with new community input is helping shape the future of safety and traffic flow on Virginia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback